PD-1: Expanding beyond cancer research

There has been significant interest in the role of programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), in modulating immune responses. The emergence of PD-1-targeted therapies has revolutionized cancer treatment, leading to a better understanding of immune checkpoint mechanisms and their uses in various research fields. This whitepaper offers a review of significant publications on the use of PD-1 antibodies in cancer, immunology, and Alzheimer’s disease research. ProSci, a Genesee Scientific brand, highlights the importance of PD-1 antibodies in resolving the complicated interactions between the immune system and pathological conditions as well as their potential to create novel therapeutic approaches.